Carmen M. M.
- Country
- Spain
- Department
- Hematology
Research Overview
- Safety and Pharmacokinetics of XMAB24306 with Daratumumab in Relapsed/Refractory Multiple Myeloma Patients
- Pharmacokinetic Comparability Study of Pre- and Post-change Teclistamab in Relapsed/Refractory Multiple Myeloma Patients
- A Study of Q702 in Patients with Relapsed or Refractory Chronic Graft-versus-Host Disease
Data & Insights
Has run more than one trial at 238 of 393 partner sites.
Specializations
Multiple Myeloma Research
The investigator specializes in treating relapsed and refractory multiple myeloma, conducting extensive research with novel therapeutic approaches including monoclonal antibodies and combination therapies.
- Advanced treatment protocols
- Novel therapeutic combinations
- High-risk myeloma management
Lymphoma Studies
Focuses on innovative treatments for diffuse large B-cell lymphoma (DLBCL) and various forms of B-cell lymphomas, with particular emphasis on developing targeted therapies for resistant disease.
- B-cell malignancy treatments
- Advanced lymphoma protocols
- Combination therapy approaches
Leukemia Treatment
Specializes in treating chronic lymphocytic leukemia and acute myeloid leukemia, with expertise in developing targeted therapeutic strategies for relapsed and refractory cases.
- Novel therapeutic agents
- Resistant disease management
- Targeted treatment approaches
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.